Custom dCas9-VPH Overexpressing Cell Line Development Service
A dCas9-VPH overexpressing cell line is a genetically engineered model that expresses dead Cas9 (dCas9) fused with the VPH transactivation domain, enabling precise gene activation without causing double-strand breaks. These cell lines are valuable tools for epigenetic regulation, gene function analysis, and transcriptional activation screening. By enabling targeted control of endogenous gene expression, they offer critical insights into gene networks and disease pathways. With strong expertise in CRISPR-based engineering, Creative Biolabs delivers customized and stable dCas9-VPH cell line development services to support diverse research and therapeutic applications.
What is dCas9-VPH?
To appreciate the transformative power of a dCas9-VPH overexpressing cell line, one must understand the sophisticated molecular architecture of the VPH complex. The "VPH" transactivation domain is a rationally designed, tripartite synthetic activator fused to the C-terminus of the dCas9 protein. It comprises three distinct and highly synergistic transcription-activating components:
- VP64: A tetrameric repeat of the Herpes Simplex Virus (HSV) VP16 activation domain. For early CRISPRa systems, VP64 alone was the standard. While it effectively recruits the RNA polymerase II initiation complex, its activation strength is often moderate when targeting promoters with high basal activity or dense chromatin structures.
- p65: The transactivating subunit of the human NF-κB complex. It acts synergistically with VP64 to recruit an overlapping but distinct set of chromatin remodeling complexes and transcription factors, significantly enhancing the transcriptional output.
- HSF1 (Heat Shock Factor 1): The activation domain of the human HSF1 protein. Unlike the Rta domain used in the dCas9-VPR system, the incorporation of HSF1 introduces a unique transactivation profile. HSF1 is highly efficient at recruiting heat shock proteins and specific chaperone networks that dramatically open chromatin accessibility at the targeted promoter or enhancer regions.
Why Choose dCas9-VPH Over Other CRISPRa Systems?
| System | Primary Function | Typical Use | Key Consideration |
|---|---|---|---|
| Cas9 overexpressing cell line | Gene knockout or editing | Loss-of-function studies, genome editing | Generates DNA double-strand breaks |
| dCas9-VPH overexpressing cell line | Gene activation | CRISPRa, gain-of-function screening | Activates endogenous genes without cutting DNA |
| dCas9-VPR overexpressing cell line | Gene activation | CRISPRa studies requiring VPR activator | Similar CRISPRa application with different activator configuration |
| dCas9-KRAB overexpressing cell line | Gene repression | CRISPRi, transcriptional silencing | Represses gene expression without cutting DNA |
dCas9-VPH is selected when the goal is to activate endogenous gene expression. It is particularly valuable for gain-of-function studies, activation screening, pathway discovery, and functional validation of genes whose upregulation may drive a phenotype.
Key Applications of dCas9-VPH Cell Lines in Gene Therapy & Research
A pre-validated dCas9-VPH overexpressing cell line serves as a foundational platform for a wide array of high-impact molecular biology and pharmacological studies.
- Drug Resistance Mechanisms: Identifying genes whose upregulation confers resistance to specific chemotherapeutics or targeted inhibitors.
- Cell Survival and Proliferation: Discovering novel oncogenes or survival factors under various stress conditions.
- Immune Evasion: Screening for surface receptors that, when activated, alter tumor-immune cell interactions.
Introduction of Custom dCas9-VPH Overexpressing Cell Line Development Service
The custom dCas9-VPH overexpressing cell line is a versatile tool for gene activation and functional genomics. It expresses dead Cas9 (dCas9)—a nuclease-inactive form of Cas9 that binds target DNA without cutting it. When fused to VPH, a synthetic activator combining VP64, p65, and HSF1, the dCas9-VPH complex enables targeted transcriptional activation of endogenous genes without genomic disruption. Establishing dCas9-VPH overexpressing cell lines enables researchers to conduct large-scale gain-of-function studies, transcriptional activation screens, and pathway elucidation. Moreover, they are compatible with a wide range of commercial CRISPR activation (CRISPRa) libraries and can also be tailored for custom sgRNA libraries targeting specific gene sets of interest, particularly valuable in studying gene regulatory networks and therapeutic target discovery.
Depending on the client's research needs, we can develop:
| Services | Descriptions |
|---|---|
| Stable dCas9-VPH bulk cell pool | Suitable for rapid pilot testing and early-stage CRISPRa feasibility studies. |
| Monoclonal dCas9-VPH overexpressing cell line | Recommended for reproducible screening, long-term studies, and standardized assays. |
| dCas9-VPH cell line with reporter background | Useful for pathway activation, promoter activity studies, and assay development. |
| dCas9-VPH cell line for pooled CRISPRa screening | Designed for compatibility with library transduction, selection, and high-throughput workflows. |
| Custom dCas9-VPH expression optimization | Suitable for sensitive or difficult-to-engineer cells requiring controlled expression levels. |
| Functional validation package | Includes gene activation testing using selected sgRNAs and downstream expression analysis. |
We do not provide a one-size-fits-all workflow. Instead, we develop each project based on the biological characteristics of the host cell, expected downstream application, expression tolerance, delivery efficiency, and screening requirements.
Cell Types We Can Support
Creative Biolabs supports dCas9-VPH overexpressing cell line development across a wide range of cell models. Cell type compatibility is a critical factor in CRISPRa performance, and our team evaluates each project to identify the most appropriate engineering and selection strategy.
Immortalized Cell Lines
Common immortalized cell lines are frequently used for CRISPRa screening, reporter assays, pathway analysis, drug response studies, and mechanistic research. These cells often support efficient viral transduction and stable selection, making them suitable for both bulk and monoclonal dCas9-VPH cell line generation.
Cancer Cell Lines
Cancer models are widely used for oncogene activation studies, resistance mechanism discovery, immune-related pathway screening, synthetic phenotype analysis, and therapeutic target validation. Creative Biolabs can develop dCas9-VPH cell lines from client-selected tumor models to support cancer biology and gene therapy-related research.
Stem Cell and Progenitor Cell Models
Stem cell-derived systems require careful handling to preserve cell identity, differentiation capacity, and growth characteristics. Creative Biolabs can help design optimized strategies for dCas9-VPH expression in stem cell or progenitor-like backgrounds where feasible.
Reporter and Engineered Backgrounds
Creative Biolabs can assess the parental cell line and develop a compatible strategy to preserve existing features while introducing dCas9-VPH.
Difficult-to-Engineer Cell Types
For these projects, we can adjust delivery conditions, selection pressure, recovery periods, clone isolation approaches, and validation endpoints to improve the likelihood of success.
How Custom dCas9-VPH Overexpressing Cell Line Development Service Can Assist Your Project
As part of our custom dCas9-VPH overexpressing cell line development service, Creative Biolabs delivers high-quality, mycoplasma-free monoclonal cell lines with robust and stable expression of dCas9-VPH. Each clone undergoes comprehensive multi-level validation, including genomic PCR, qPCR, Western blot, and expression/functionality assays to ensure high expression fidelity and transcriptional activation efficiency. These rigorously verified cell lines are ready-to-use and compatible with both commercial and custom CRISPRa libraries, enabling clients to conduct accurate gene activation, functional screening, and pathway analysis with confidence and reproducibility.
Workflow of Custom dCas9-VPH Overexpressing Cell Line Development Service
Figure. 1 Workflow of our custom dCas9-VPH overexpressing cell line development service.
Case Study: Accelerating Melanoma Drug Resistance Research
- The Challenge: A leading oncology research institute approached us aiming to conduct a genome-wide CRISPRa screen to identify novel genes that, when overexpressed, confer resistance to a new BRAF inhibitor in melanoma. They previously attempted to generate their own stable cell line using a multi-vector SAM system but suffered from very low viability and inconsistent gene activation, halting their project for 5 months.
-
Our Solution: Our team proposed switching to the highly potent, single-component dCas9-VPH system. We utilized the client's preferred A375 melanoma cell line.
- We constructed a custom lentiviral vector carrying dCas9-VPH under an EF1α promoter linked to a Blasticidin resistance gene.
- We generated ultra-high-titer lentivirus and transduced the A375 cells at an optimized MOI to ensure single-copy integration, minimizing toxicity.
- Following selection, we isolated 50 single-cell clones and screened them for robust dCas9-VPH expression via Western blot.
- The top 3 clones were functionally validated using an sgRNA targeting the TTN gene (a massive gene notoriously difficult to activate).
- The Result: We delivered the validated A375-dCas9-VPH monoclonal cell line within 8 weeks. The client immediately proceeded with their genome-wide sgRNA library transduction, successfully identifying three novel kinase targets driving drug resistance, paving the way for a major publication and subsequent dual-inhibition therapeutic strategies.
Advantages of Custom dCas9-VPH Overexpressing Cell Line Development Service
- Flexible Workflow but not simple - A customizable and flexible development process tailored to client needs, helping simplify downstream experiments and ensure smooth project progression.
- Strict Quality Control - Rigorous validation ensures stable integration and high-level expression of dCas9-VPH, guaranteeing reliable and reproducible gene activation performance.
- Broad Cell Type Compatibility - Compatible with a wide variety of cell types, including immortalized cell lines, stem cells, and primary cells, to meet diverse research needs.
- High-Throughput Ready - Fully supports large-scale functional screening using both commercial CRISPRa libraries and customized sgRNA libraries for targeted studies.
- Comprehensive Support - End-to-end technical assistance, timely communication, and dependable after-sales service ensure a seamless and satisfying customer experience.
What You Receive
Creative Biolabs provides deliverables according to the agreed project scope. A typical dCas9-VPH overexpressing cell line development project may include:
1. Engineered dCas9-VPH Cell Line
Clients receive a stable cell population or monoclonal cell line expressing dCas9-VPH. The final format depends on project goals, cell type, and required validation level.
2. Validated Clone or Cell Pool
For monoclonal projects, candidate clones are screened and the best-performing clone or clones are selected based on expression, growth, and functional performance.
3. Quality Control Data
QC data may include genomic confirmation, expression analysis, functional activation testing, cell viability, morphology observations, mycoplasma testing, and other project-specific assays.
4. Project Report
A final report summarizes the development workflow, methods, validation results, culture recommendations, and handling notes.
5. Technical Support
Creative Biolabs provides technical support to help clients use the delivered cell line in downstream CRISPRa experiments, guide RNA testing, or screening workflows.
Customer Reviews
Frequently Asked Questions (FAQ)
Q: What is a dCas9-VPH overexpressing cell line?
A: A dCas9-VPH overexpressing cell line is a genetically engineered cell model that stably expresses nuclease-inactive Cas9 fused to the VPH transcriptional activation domain. It can be directed by sgRNAs to activate endogenous gene expression without introducing DNA double-strand breaks.
Q: How is dCas9-VPH different from regular Cas9?
A: Regular Cas9 cuts DNA and is commonly used for knockout or genome editing. dCas9 lacks nuclease activity, so it binds DNA without cutting it. When fused to VPH, dCas9 becomes a programmable gene activation tool.
Q: Can this cell line be used for CRISPRa screening?
A: Yes. A validated dCas9-VPH overexpressing cell line can be used with pooled or arrayed sgRNA libraries for CRISPR activation screening. It is suitable for gain-of-function studies and endogenous gene activation screens.
Q: Do you provide monoclonal cell lines or only bulk pools?
A: Creative Biolabs can provide both. Bulk pools may be suitable for rapid feasibility studies, while monoclonal lines are recommended for reproducible experiments, long-term studies, and high-throughput screening.
Q: What validation methods are available?
A: Validation may include genomic PCR, qPCR, Western blot, fluorescence analysis, functional gene activation assays, mycoplasma testing, viability assessment, and growth evaluation. The exact validation package can be customized.
Partner with the Experts in Genetic Engineering
Creative Biolabs provides customized dCas9-VPH overexpressing cell line development services designed to meet the practical needs of modern gene function research. From project design and vector construction to stable integration, clone screening, functional validation, and final delivery, our team supports each step with technical expertise and rigorous quality control. Contact us today to discuss your research goals and request a customized proposal for dCas9-VPH overexpressing cell line development.
